Home > Dermatology > WCD 2019 > Lupus Erythematosus Today > New targets and biologics for cutaneous lupus erythematosus

New targets and biologics for cutaneous lupus erythematosus

Presented By
Prof. Victoria P. Werth, University of Pennsylvania, USA
WCD 2019

Prof. Victoria P. Werth (University of Pennsylvania, USA) pointed out the need for new therapeutics in cutaneous lupus erythematosus (CLE) for patients resistant to conventional immunosuppressive agents [1].

Most therapeutic trials with novel agents focus on systemic lupus erythematosus (SLE) and exclude CLE patients. However, CLE and SLE share the same pathology. To solve this gap, a lupus community panel proposed to optimise future clinical trials [2]. If skin improvement is strong enough when nested in an SLE study, treatment should be made available for patients with CLE irrespective of whether they meet SLE classification. A couple of biologics have shown activity in CLE, including the IL-12/IL-23 inhibitor ustekinumab. Ustekinumab was shown to result in significant improvement in disease activity, assessed in the responder index 4 in the SLE disease activity index 2000 (SLEDAI-2K) [3].

B cells: an important novel target

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on